ArticleNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015
Genome-wide association study of copy number variations (CNVs) with opioid dependence.
Article in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Genome-wide meta-analysis of copy number variations with alcohol dependence.The pharmacogenomics journal · 2018Pooled it
- Epigenetic manipulation of anterior insular cortex alters neural signals and cognitive control.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025Article
- Pentilludin reduces rat amphetamine and remifentail self-administration with good pharmacologic and toxicologic profiles.bioRxiv : the preprint server for biology · 2025Article
- Trans-synaptic modulation of cholinergic circuits tunes opioid reinforcement.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Mosaic Chromosomal Alterations/Somatic Copy Number Variations: A New Frontier in Genetic Association Studies of Complex Diseases.Biological psychiatry · 2025Article
- The genetic landscape of substance use disorders.Molecular psychiatry · 2024Review
- Genome-wide analyses reveal novel opioid use disorder loci and genetic overlap with schizophrenia, bipolar disorder, and major depression.Addiction biology · 2023Article
- The Genetically Informed Neurobiology of Addiction (GINA) model.Nature reviews. Neuroscience · 2023Review
- Genetics of psycho-emotional well-being: genome-wide association study and polygenic risk score analysis.Frontiers in psychiatry · 2023Article
- Selecting the appropriate hurdles and endpoints for pentilludin, a novel antiaddiction pharmacotherapeutic targeting the receptor type protein tyrosine phosphatase D.Frontiers in psychiatry · 2023Review
- Novel digital approaches to the assessment of problematic opioid use.BioData mining · 2022Review
- Strong and weak cross-inheritance of substance use disorders in a nationally representative sample.Molecular psychiatry · 2022Article
- Structure-activity studies of PTPRD phosphatase inhibitors identify a 7-cyclopentymethoxy illudalic acid analog candidate for development.Biochemical pharmacology · 2022Article
- Genomic and Personalized Medicine Approaches for Substance Use Disorders (SUDs) Looking at Genome-Wide Association Studies.Biomedicines · 2021Review
- Genetics of substance use disorders: a review.Psychological medicine · 2021Article
- The phenomics and genetics of addictive and affective comorbidity in opioid use disorder.Drug and alcohol dependence · 2021Review
- Genetic variation regulates opioid-induced respiratory depression in mice.Scientific reports · 2020Article
- Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic.Expert opinion on drug metabolism & toxicology · 2020Review
- Stratified analyses of genome wide association study data reveal haplotypes for a candidate gene on chromosome 2 (KIAA1211L) is associated with opioid use in patients of Arabian descent.BMC psychiatry · 2020Article
- Genome-Wide Association Study of Opioid Cessation.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
Abstract
Single-nucleotide polymorphisms that have been associated with opioid dependence (OD) altogether account for only a small proportion of the known heritability. Most of the genetic risk factors are unknown. Some of the 'missing heritability' might be explained by copy number variations (CNVs) in the human genome. We used Illumina HumanOmni1 arrays to genotype 5152 African-American and European-American OD cases and screened controls and implemented combined CNV calling methods. After quality control measures were applied, a genome-wide association study (GWAS) of CNVs with OD was performed. For common CNVs, two deletions and one duplication were significantly associated with OD genome-wide (eg, P=2 × 10(-8) and OR (95% CI)=0.64 (0.54-0.74) for a chromosome 18q12.3 deletion). Several rare or unique CNVs showed suggestive or marginal significance with large effect sizes. This study is the first GWAS of OD using CNVs. Some identified CNVs harbor genes newly identified here to be of biological importance in addiction, whereas others affect genes previously known to contribute to substance dependence risk. Our findings augment our specific knowledge of the importance of genomic variation in addictive disorders, and provide an addiction CNV pool for further research. These findings require replication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.